FDA Approves Donanemab as ‘Breakthrough Treatment’ for Alzheimer’s

BREAKTHROUGH: The US Food and Drug Administration (FDA) has granted a “Breakthrough Therapy” designation for donanemab, a potential new treatment for people with early symptomatic Alzheimer’s. Find out more.

Read more »